Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials.

ABSTRACT:

Objective

Our objective of this study was to analyse all oncological clinical trials using regorafenib to create a complete risk/benefit profile for the drug.

Background

Creating a novel chemotherapy is costly both in time and capital spent for drug manufacturers. To regenerate what they've spent, drug manufacturers may attempt to repurpose their medications for new indications via clinical trials. To fully understand the risk/benefits in comparison to a drug's efficacy, a pooled analysis must be completed.

Methods

We screened PubMed, Embase, Cochrane (CENTRAL) and ClinicalTrials.gov for trials of regorafenib used to treat solid cancers. Next, we extracted median progression-free survival and overall survival in months, adverse event rates and objective response rate

SUBMITTER: Dennis B 

PROVIDER: S-EPMC11234991 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature